Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Consensus Rating of “Moderate Buy” from Analysts

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) has received a consensus rating of “Moderate Buy” from the fifteen research firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $137.3333.

Several brokerages recently weighed in on MIRM. Weiss Ratings upgraded Mirum Pharmaceuticals from a “sell (d-)” rating to a “sell (d)” rating in a research report on Thursday, August 6th. Morgan Stanley set a $137.00 price objective on shares of Mirum Pharmaceuticals in a research note on Thursday, August 6th. Stifel Nicolaus set a $136.00 target price on shares of Mirum Pharmaceuticals in a report on Thursday, May 7th. Royal Bank Of Canada cut their target price on shares of Mirum Pharmaceuticals from $148.00 to $135.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Finally, Wall Street Zen upgraded shares of Mirum Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday.

Mirum Pharmaceuticals Price Performance

Shares of NASDAQ MIRM opened at $98.23 on Friday. The business’s 50 day moving average price is $110.50 and its 200 day moving average price is $101.94. The firm has a market cap of $6.38 billion, a P/E ratio of -6.75 and a beta of 0.52. Mirum Pharmaceuticals has a 52 week low of $63.23 and a 52 week high of $130.00. The company has a quick ratio of 2.74, a current ratio of 2.86 and a debt-to-equity ratio of 1.28.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.32). Mirum Pharmaceuticals had a negative return on equity of 36.28% and a negative net margin of 139.18%.The business had revenue of $176.24 million for the quarter, compared to analysts’ expectations of $166.33 million. During the same period in the prior year, the business posted ($0.12) earnings per share. The business’s quarterly revenue was up 37.9% compared to the same quarter last year. On average, sell-side analysts expect that Mirum Pharmaceuticals will post -1.24 earnings per share for the current year.

Insider Buying and Selling at Mirum Pharmaceuticals

In other news, CFO Eric Bjerkholt sold 5,000 shares of the firm’s stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $122.25, for a total transaction of $611,250.00. Following the sale, the chief financial officer directly owned 42,181 shares in the company, valued at $5,156,627.25. This trade represents a 10.60% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher Peetz sold 30,000 shares of Mirum Pharmaceuticals stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $95.84, for a total value of $2,875,200.00. Following the completion of the transaction, the chief executive officer owned 194,309 shares of the company’s stock, valued at approximately $18,622,574.56. This represents a 13.37% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 87,155 shares of company stock valued at $9,164,062. Corporate insiders own 8.32% of the company’s stock.

Hedge Funds Weigh In On Mirum Pharmaceuticals

A number of hedge funds have recently bought and sold shares of MIRM. BlackRock Inc. acquired a new position in shares of Mirum Pharmaceuticals during the 2nd quarter worth about $513,945,000. Janus Henderson Group PLC boosted its holdings in Mirum Pharmaceuticals by 21.4% in the 4th quarter. Janus Henderson Group PLC now owns 6,065,308 shares of the company’s stock worth $479,050,000 after buying an additional 1,067,722 shares during the last quarter. State Street Corp increased its stake in Mirum Pharmaceuticals by 59.2% during the 4th quarter. State Street Corp now owns 2,143,992 shares of the company’s stock worth $169,354,000 after buying an additional 797,088 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of Mirum Pharmaceuticals by 566.8% during the third quarter. Wellington Management Group LLP now owns 790,689 shares of the company’s stock valued at $57,965,000 after acquiring an additional 672,118 shares during the last quarter. Finally, Bank of New York Mellon Corp acquired a new position in shares of Mirum Pharmaceuticals during the second quarter valued at approximately $78,434,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.